Congress Wealth Management LLC DE Sells 4,277 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Congress Wealth Management LLC DE cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,415 shares of the company’s stock after selling 4,277 shares during the period. Congress Wealth Management LLC DE owned 0.11% of Medpace worth $9,936,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. RiverPark Advisors LLC acquired a new position in Medpace in the fourth quarter valued at $26,000. Contravisory Investment Management Inc. bought a new stake in Medpace in the fourth quarter worth approximately $26,000. GAMMA Investing LLC acquired a new position in Medpace in the fourth quarter valued at approximately $30,000. McGlone Suttner Wealth Management Inc. bought a new position in shares of Medpace during the 4th quarter worth approximately $33,000. Finally, Principal Securities Inc. acquired a new stake in shares of Medpace during the 4th quarter worth approximately $68,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 4,782 shares of the firm’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $400.58, for a total value of $1,915,573.56. Following the completion of the sale, the chief executive officer now directly owns 716,197 shares of the company’s stock, valued at $286,894,194.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO August J. Troendle sold 4,782 shares of Medpace stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total value of $1,915,573.56. Following the completion of the transaction, the chief executive officer now directly owns 716,197 shares in the company, valued at approximately $286,894,194.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 15,102 shares of the stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total value of $6,051,220.38. Following the sale, the chief executive officer now owns 791,541 shares in the company, valued at approximately $317,162,563.29. The disclosure for this sale can be found here. Insiders have sold 145,291 shares of company stock worth $59,648,117 in the last ninety days. Company insiders own 20.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on MEDP shares. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. Guggenheim boosted their price objective on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 price target for the company. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and raised their price objective for the company from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Finally, Robert W. Baird boosted their target price on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Medpace presently has an average rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Stock Performance

NASDAQ:MEDP traded down $0.03 on Friday, hitting $390.55. The stock had a trading volume of 112,402 shares, compared to its average volume of 190,675. Medpace Holdings, Inc. has a 1 year low of $199.20 and a 1 year high of $421.00. The firm’s fifty day simple moving average is $395.33 and its two-hundred day simple moving average is $345.62. The stock has a market cap of $12.10 billion, a P/E ratio of 39.81, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The company had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. During the same period last year, the business posted $2.27 earnings per share. Medpace’s revenue was up 17.7% on a year-over-year basis. Equities research analysts predict that Medpace Holdings, Inc. will post 11.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.